Objective: A human pilot study testing the safety and effectiveness of NT (Number Ten), a dietary herbal supplement made from rhubarb, ginger, astragulus, red sage and turmeric, to reduce food intake and cause weight loss. Research methods and procedures: A total of 24 healthy women, 18-60 years, body mass index 25-35 kg/m 2 on no chronic medication were randomized to four groups of six: (1) oral freeze-dried NT 6 gm/day, (2) bed-dried NT 6 gm/day, (3) freezedried NT 12 gm/day or (4) placebo. Number Ten dose was escalated over 3 weeks and maintained for 8 weeks on a 700 kcal/day diet below maintenance. Food intake was measured at baseline and 4 weeks. Safety parameters were monitored weekly during dose escalation, week 6 and week 12.
Background
Wei Kai-yuan, Ph D, now deceased, was trained in Beijing, China at a Catholic University before Chairman Mao becoming head of the Chinese government in 1949. Dr Wei's father, a traditional Chinese doctor, taught him the principals of traditional Chinese medicine. Dr Wei developed an interest in obesity and developed an herbal decoction (tea) that he called NT (Number Ten). This herbal decoction was derived empirically using the principles of traditional Chinese medicine, but tested in rodents using western scientific principles.
The herbal decoction consisted of a combination of 40% rhubarb root and stem (radix et rhizoma rhei), 13.3% astragulus root (radix astragali), 13.3% red sage root (radix salviae miltiorrhizae), 26-27% turmeric (rhizoma curcumae longae) and 6-7% dried ginger (rhizoma zingiberis officinalis). The rhubarb is placed in a stainless-steel pot with six to eight times its weight in water and the mixture of the four other herbs are prepared in a like manner. The herbs are allowed to soak for 8 h. The water in the four-herb pot is brought to a boil until the volume is reduced by half. The cold rhubarb decoction is then added to the four-herb mixture and heated to just below boiling for 20 min before being allowed to cool. After filtering the large particulate matter from the decoction, the remaining liquid was then freeze-dried to a powder that produced 0.5 g of solids from 10 ml of liquid.
Dr Wei tested the NT developed as described in the foregoing paragraph in the following ways: 1 1. Male Sprague-Dawley rats were made obese (average weight 620 g) with a high sugar diet and treated for 90 days with NT 2.5 g or NT 5 g of dried powder per day orally by gavage. The rats on 2.5 and 5 g/day of NT lost 30 and 40% of their weight, respectively compared to their untreated controls. A 90% drop in triglycerides, a 60% drop in total cholesterol, a 70% drop in low-density lipoprotein cholesterol and a 70% increase in highdensity lipoprotein cholesterol accompanied the 40% weight loss. 2. Male and female Wistar rats were made obese using monosodium glutamate to damage the hypothalamic controls of weight. The male (average weight 580 g) and the female (average weight 430 g) rats were treated with 2.5 or 5 g of NT powder per day by gavage. The male rats lost 36 and 41% of their body weight and the females lost 33 and 42% of their body weight compared to the control in the 2.5 and 5 g/day groups, respectively. 3. Young growing male Wistar rats (average weight 220 g) were placed on a high sugar obesity-inducing diet and given one of the following by gavage daily for 90 days: 1 g of NT powder, 1.5 g of NT powder, 5 g of NT powder, 0.22 mg fenfluramine or control. At the end of 90 days, the weight, respectively, in the five groups was 420, 400, 400, 360 and 450 g.
Dr Wei came to the Pennington Biomedical Research Center (PBRC) with the herbs from China, presented the unpublished data described above and demonstrated the techniques of making the decoction. A study similar to number 3 above was then performed at PBRC after Dr Wei returned to China, confirming his results. Owing to the safety and efficacy of NT in rodent studies and owing to the ingredients of NT being classified as food, human studies were undertaken to test the safety and efficacy of NT in the treatment of human obesity.
Number Ten was first tested in a single healthy male who took escalating doses of NT starting at 0.7 g/day and reaching 6 g/ day over a 12-day period. He experienced no adverse events, his appetite decreased and he lost 1.8 kg (4 pounds) over 12 days. The NT used in the animal studies was prepared using a freeze-drying process. Bed-drying is more economical for the production of a commercial dietary herbal supplement. The following pilot study was designed to test safety and efficacy of NT in reducing body weight and food intake using two different doses of NT and at the lower dose, prepared by two different processes.
Materials and methods
Twenty-four healthy non-pregnant, non-lactating women between the ages of 18 and 60 years of age with a body mass index between 25 and 35 kg/m 2 taking no chronic medication other than oral contraceptives or hormone replacement therapy participated in this study. The PBRC Institutional Review Board (IRB) approved this study, and all subjects gave their written informed consent before participation. Subjects had a medical history, physical examination, Complete Blood Count (CBC) chemistry panel, urinalysis and electrocardiogram at screening. A registered dietitian instructed the subjects in a diet 700 kcal/d below weight maintenance requirements based on the WHO formula at baseline. 2 
Weight loss
Subjects were randomized to oral freeze-dried NT 6 g/day (six subjects), bed-dried NT 6 g/day (six subjects), freeze-dried NT 12 g/day (six subjects), or placebo (six subjects). Capsules contained 250 mg of NT (freeze-dried), 341 mg (spray dried -250 mg of NT and the rest vehicle), 500 mg of NT (freeze-dried) or placebo supplied by Deseret Laboratories International, St George, Ut, USA. The medication dose was escalated over a 3-week period starting with 1 pill/day on day 1 and increasing by 1 pill/ day during the first week until 6 pills/ day were reached. Subjects increased the number of pills by 1 pill/ day in the second week until 12 pills/ day were reached. The subjects increased their pills by 2/ day in the third week until 24 pills a day were reached (six pills four times per day). The two doses of NT based on the metabolic mass equation were approximately 1 12 and 1 6 of the dose equivalents of those given to the rats in the animal studies with NT. 3 Although there is a controversy over the exponent in the metabolic mass equation being 0.75 or 0.67, we chose 0.67 based on the arguments of Heusner. 3, 4 Subjects were evaluated weekly during the 11-week study and then 1 week later for a follow-up period at week 12. At each weekly clinic visit, subjects were weighed, blood pressure was measured, pulse was taken, medications were dispensed, used medication bottles returned for compliance check and subjects were questioned about any adverse events. The CBC, chemistry panel, urinalysis and electrocardiogram were repeated weekly during dose escalation, and at weeks 6 and 11. Physical examination was repeated on week 11. Subjects returned on week 12 to evaluate their response to stopping medication.
Food intake testing
Subjects had food intake evaluated with a universal eating monitor at baseline and at the end of week 4. Subjects visited the food intake laboratory after an overnight fast during which only water was allowed. Subjects completed visual analog scales (VAS) of appetite and a questionnaire about factors that might affect taste such as colds or allergies. The VAS consisted of ratings of hunger, satiety, desire to eat and prospective food consumption (PFC -how much could you eat at this moment). Visual analog scales were completed before and after each test meal. Participants were given six pills to swallow and the food intake test occurred 1 h later. Participants were given a meal of sandwich quarters, chips and cookies larger than they could reasonably eat, and they were allowed to eat as much or as little as they wished for 20 min. The subjects were given placebo on the first visit and the treatment to which they were randomized on week 4. 
Statistical analysis
The mixed linear model with repeated measures analysis was used to compare weight loss, laboratory tests, blood pressure and pulse in the NT and placebo groups. The w 2 test was used to compare the demographic data. The primary study end points were body weight and food intake. Secondary endpoints were safety measures (blood pressure, pulse, laboratory tests, adverse events and electrocardiograms). Food intake was analyzed by calculating change in food intake from baseline (total kcal consumed at week 4 minus total kcal consumed at baseline). Differences in these change scores between the four groups of participants were evaluated with univariate analysis of variance (ANOVA). Food intake at baseline was entered into the model as a covariate. Visual analog scale data were analyzed by calculating change scores for the ratings that were collected before the meal at baseline and week 4 (week 4 pre-meal VAS rating minus baseline pre-meal VAS rating). Similar change scores were calculated for the ratings collected after the meals. These change scores were compared among the four groups of participants with one-way ANOVA. Because four VAS scales were analyzed (hunger, satiety, desire to eat and PFC), alpha was adjusted to 0.0125 based on the Bonferroni procedure. Owing to the pilot nature of this trial, statistical significance was not expected.
Results
Subjects were well matched for age, weight and body mass index (Table 1 ). There were three dropouts during the trial: -two in the NT 250 mg group (one for loose stools and one that was lost to follow-up) and one in the NT 500 mg group (for cramps and loose stools). Medication compliance based on pill counts was 495%.
Weight loss
Weight loss at 12 weeks was 1.8 kg in the placebo group and 0.4 kg in the 500 mg NT group, whereas the 250 mg bed-and freeze-dried groups gained 0.43 and 0.87 kg, respectively. These weight losses and gains were not statistically different from one another (Figure 1 ).
Food intake
The group effect for the univariate ANOVA was significant, F(3, 18) ¼ 3.87, Po0.05, indicating that the food intake change scores differed by group. Food intake increased from baseline to week 4 by 12.9 kcal in the placebo group and 74 kcal in the 250 mg freeze-dried group. Alternatively, food intake decreased by 49.5 kcal in the 250 mg bed-dried group and 193.7 kcal in the 500 mg freeze-dried group (Figure 2 ). Contrasts indicated that the difference scores for the 250 mg freeze-dried group and the 500 mg freeze-dried group Herbal supplement and weight loss FL Greenway et al differed significantly (Po0.01), but none of the treatment groups differed significantly from the placebo group (P-values 40.10). After alpha adjustment, VAS change scores for the ratings that were collected before the meals differed only for the desire to eat: ratings of hunger (P ¼ 0.11), satiety (P ¼ 0.055), desire to eat (P ¼ 0.04) and PFC (P ¼ 0.24). In addition, VAS change scores for ratings that were collected after the meals did not differ by group for hunger (P ¼ 0.64), satiety (P ¼ 0.48), desire to eat (P ¼ 0.58) or PFC (P ¼ 0.60).
Safety
Pulse and blood pressure fluctuated within the normal range and there were no dose-related changes in pulse or blood pressure. Likewise, the chemistry panels, CBC's and urinalyses had some fluctuations within the normal range, but there were no dose-related changes seen. There were no significant changes in the physical findings on the end of study physical examinations, and no electrocardiogram changes were seen in the course of the study. Adverse events are summarized in Table 2 . There was no diarrhea in the placebo group, 33% of both 250 mg NT experienced diarrhea and 67% of the 500 mg NT group experienced diarrhea. The placebo group averaged 0.16 soft stools per day, the 250 mg NT groups averaged 0.6 soft stools per day and the 500 mg NT group averaged 2.83 soft stools per day. There was clearly a dose-related problem of loose stools induced by the NT in this human pilot trial, and it became apparent that further increases in the dose of NT would not be tolerated.
Analysis of Number Ten
Number Ten contained sennosides and rhein ( Figure 3 ). Gallic acid was also identified as a component of NT ( Figure 4 ). Figure 2 Food intake difference scores (week 4 minus baseline). 3 After titration to the full dose, subjects were followed for an 8-week weight loss program.
There was not only a lack of a statistically significant weight loss, but, more importantly, all doses of NT gave less weight loss than the placebo group. The food intake change scores for the 250 mg freeze-dried NT group and the 500 mg NT group differed significantly, but none of the treatment groups' food intake change scores differed significantly from placebo. Although one might be tempted to conclude that the 500 mg dose was possibly effective, there is no logical explanation for the significant increase in food intake in the 250 mg freeze-dried NT group, and the lack of weight loss in this study makes any effect on food intake moot. Although NT seemed to be well tolerated in rodents, the rats did have some softening of the stools at doses six to 24 times those given in this human pilot study. It is clear from this pilot study that doses equivalent to those that were effective for weight loss in rodents will not be tolerated in humans. The analysis of NT demonstrated the presence of sennosides and rhein, compounds utilized as herbal laxatives, and their presence is presumably responsible for the loose stools seen in the study.
Gallic acid is another component of NT. Gallic acid is a component of gallotannins and has been shown to decrease food intake in rats. 5 As gallic acid reduces food intake when given as an intravenous infusion and when given orally, the mechanism of action in reducing food intake and body weight is not mediated entirely by taste aversion. Gallic acid is available in herbal form as gallnut extract. Thus, if gallic acid decreases food intake in humans as well as in rodents, one might be able to supplement NT with sufficient gallic acid to achieve efficacy without inducing loose stools.
In conclusion, despite the encouraging studies in rodents, NT does not have potential as a dietary herbal supplement in humans owing to gastrointestinal toxicity below doses that are effective for weight loss.
